Xvivo Perfusion reported 34% revenue growth and 21% EBITDA margin in Q3 2026, with European CE approval and U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results